Cargando…
Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
OBJECTIVES: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitali...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242694/ https://www.ncbi.nlm.nih.gov/pubmed/35779764 http://dx.doi.org/10.1016/j.cmi.2022.06.019 |
_version_ | 1784738107434729472 |
---|---|
author | Epaulard, Olivier Abgrall, Sophie Lefebvre, Maeva Faucher, Jean-François Michon, Jocelyn Frentiu, Emilia Blanchi, Sophie Janssen, Cécile Charbonnier, Gabrielle Fresse, Audrey Laurent, Simon Sandjakian, Lena Casez, Pierre Mahamat, Aba Beraud, Guillaume |
author_facet | Epaulard, Olivier Abgrall, Sophie Lefebvre, Maeva Faucher, Jean-François Michon, Jocelyn Frentiu, Emilia Blanchi, Sophie Janssen, Cécile Charbonnier, Gabrielle Fresse, Audrey Laurent, Simon Sandjakian, Lena Casez, Pierre Mahamat, Aba Beraud, Guillaume |
author_sort | Epaulard, Olivier |
collection | PubMed |
description | OBJECTIVES: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitalised patients according to vaccine status. METHODS: We performed a retrospective observational study on patients hospitalised in 10 centres with a SARS-CoV-2 infection (Delta variant) from July to November 2021 by including all patients who had completed their primary vaccination at least 14 days before hospital admission and the same number of completely unvaccinated patients. We assessed the impact of vaccination and other risk factors through logistic regression. RESULTS: We included 955 patients (474 vaccinated and 481 unvaccinated). Vaccinated patients were significantly older (75.0 [63.25-84.0] vs. 55.0 [38.0-73.0]; p < 0.001), more frequently males (55.1% (261/474) vs. 46.4% (223/481); p = 0.009), and had more comorbidities (2.0 [1.0-3.0] vs. 1.0 [0.0-2.0]; p < 0.001). Vaccinated patients were less often admitted for Covid-19 (59.3% (281/474) vs. 75.1% (361/481); p < 0.001), had less extended lung lesions (≤25%: 64.3% (117/182) vs. 38.4% (88/229); p < 0.001), required oxygen less frequently (57.5% (229/398) vs. 73.0% (270/370); p < 0.001), at a lower flow (3.0 [0.0-8.7] vs. 6.0 [2.0-50.0] L/min, p < 0.001), and for a shorter duration (3 [0.0-8.0] vs. 6 [2.0-12.0] days, p < 0.001)., and required less frequently intensive care unit admission (16.2% (60/370) vs. 36.0% (133/369); p < 0.001) but had comparable mortality in bivariate analysis (16.7% (74/443) vs. 12.2% (53/433); p = 0.075). Multivariate logistic regression showed that vaccination significantly decreased the risk of death (0.38 [0.20-0.70](p = 0.002), ICU admission (0.31 [0.21-0.47](p < 0.001) and oxygen requirement (0.16 [0.10-0.26](p < 0.001), even among older patients or with comorbidities. CONCLUSIONS: Among patients hospitalised with a delta variant SARS-CoV-2 infection, vaccination was associated with less severe forms, even in the presence of comorbidities. |
format | Online Article Text |
id | pubmed-9242694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92426942022-06-30 Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection Epaulard, Olivier Abgrall, Sophie Lefebvre, Maeva Faucher, Jean-François Michon, Jocelyn Frentiu, Emilia Blanchi, Sophie Janssen, Cécile Charbonnier, Gabrielle Fresse, Audrey Laurent, Simon Sandjakian, Lena Casez, Pierre Mahamat, Aba Beraud, Guillaume Clin Microbiol Infect Original Article OBJECTIVES: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitalised patients according to vaccine status. METHODS: We performed a retrospective observational study on patients hospitalised in 10 centres with a SARS-CoV-2 infection (Delta variant) from July to November 2021 by including all patients who had completed their primary vaccination at least 14 days before hospital admission and the same number of completely unvaccinated patients. We assessed the impact of vaccination and other risk factors through logistic regression. RESULTS: We included 955 patients (474 vaccinated and 481 unvaccinated). Vaccinated patients were significantly older (75.0 [63.25-84.0] vs. 55.0 [38.0-73.0]; p < 0.001), more frequently males (55.1% (261/474) vs. 46.4% (223/481); p = 0.009), and had more comorbidities (2.0 [1.0-3.0] vs. 1.0 [0.0-2.0]; p < 0.001). Vaccinated patients were less often admitted for Covid-19 (59.3% (281/474) vs. 75.1% (361/481); p < 0.001), had less extended lung lesions (≤25%: 64.3% (117/182) vs. 38.4% (88/229); p < 0.001), required oxygen less frequently (57.5% (229/398) vs. 73.0% (270/370); p < 0.001), at a lower flow (3.0 [0.0-8.7] vs. 6.0 [2.0-50.0] L/min, p < 0.001), and for a shorter duration (3 [0.0-8.0] vs. 6 [2.0-12.0] days, p < 0.001)., and required less frequently intensive care unit admission (16.2% (60/370) vs. 36.0% (133/369); p < 0.001) but had comparable mortality in bivariate analysis (16.7% (74/443) vs. 12.2% (53/433); p = 0.075). Multivariate logistic regression showed that vaccination significantly decreased the risk of death (0.38 [0.20-0.70](p = 0.002), ICU admission (0.31 [0.21-0.47](p < 0.001) and oxygen requirement (0.16 [0.10-0.26](p < 0.001), even among older patients or with comorbidities. CONCLUSIONS: Among patients hospitalised with a delta variant SARS-CoV-2 infection, vaccination was associated with less severe forms, even in the presence of comorbidities. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-12 2022-06-30 /pmc/articles/PMC9242694/ /pubmed/35779764 http://dx.doi.org/10.1016/j.cmi.2022.06.019 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Epaulard, Olivier Abgrall, Sophie Lefebvre, Maeva Faucher, Jean-François Michon, Jocelyn Frentiu, Emilia Blanchi, Sophie Janssen, Cécile Charbonnier, Gabrielle Fresse, Audrey Laurent, Simon Sandjakian, Lena Casez, Pierre Mahamat, Aba Beraud, Guillaume Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection |
title | Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection |
title_full | Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection |
title_fullStr | Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection |
title_full_unstemmed | Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection |
title_short | Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection |
title_sort | impact of vaccination on the symptoms of hospitalised patients with sars-cov-2 delta variant (b.1.617.1) infection |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242694/ https://www.ncbi.nlm.nih.gov/pubmed/35779764 http://dx.doi.org/10.1016/j.cmi.2022.06.019 |
work_keys_str_mv | AT epaulardolivier impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT abgrallsophie impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT lefebvremaeva impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT faucherjeanfrancois impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT michonjocelyn impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT frentiuemilia impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT blanchisophie impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT janssencecile impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT charbonniergabrielle impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT fresseaudrey impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT laurentsimon impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT sandjakianlena impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT casezpierre impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT mahamataba impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection AT beraudguillaume impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection |